Drug composition for treating cerebral infarction or/and coronary heart disease stenocardia and preparation method and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for coronary heart disease angina pectoris and a composition is applied in the field of pharmaceutical compositions for the treatment of cerebral infarction or/and coronary heart disease angina pectoris, and can solve problems such as difficulty in obtaining curative effects and the like
Active Publication Date: 2015-04-22
SICHUAN CHUANDA WEST CHINA PHARMA
View PDF2 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0008] Existing studies have shown that cardiovascular and cerebrovascular diseases are a complex, dynamic and continuous process, a multi-link, mul
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0022] Embodiment 1: pharmaceutical composition tablet of the present invention
[0023] Weigh 16g of paeoniflorin, 6g of hydroxysafflower pigment A, and 0.2g of rutin, mix well, add 140g of starch, 33g of dextrin and 5.5g of powdered sugar, add 5% starch slurry to make soft material, pass through a 16-mesh sieve to make wet granules , dry the wet granules at 60-70°C, sieve the dry granules with a 20-mesh sieve, add 2% magnesium stearate, mix them evenly, and compress them into tablets.
Embodiment 2
[0024] Embodiment 2: pharmaceutical composition capsule of the present invention
[0025] Weigh 14g of paeoniflorin, 8g of hydroxysafflower pigment A, and 0.4g of rutin, mix well, add 110g of starch, 63g of dextrin and 5g of powdered sugar, add 85% ethanol to make soft material, pass through a 20-mesh sieve to make wet granules, The wet granules were dried at 60-70°C, and the dry granules were sieved with a 20-mesh sieve to make 200g, and divided into 0.2g / capsules to make 1,000 granules in total.
Embodiment 3
[0026] Embodiment 3: pharmaceutical composition granule of the present invention
[0027] Weigh 60g of paeoniflorin, 30g of hydroxysafflower pigment A, and 3g of rutin, mix evenly, fluidize with lactose in an intermittent fluidized bed, dry, add 85% ethanol to make soft material, pass through a 20-mesh sieve to make wet granules , dry the wet granules at 60-70°C, sieve the granules with a 20-mesh sieve, make 1000g, and pack them into 3g / bags.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a drug composition for treating cerebral infarction or/and coronary heart disease stenocardia. The drug composition is prepared from the following active ingredients of, by weight, 1-10 parts of paeoniflorin, 1-5 parts of hydroxyl safflower pigment A and 0.1-0.5 part of rutin. The invention further provides a preparation method and application of the drug composition. The problems that only one single drug is used, action targets are fewer, the drug achieves the treatment purpose through one target, and the consumed drug dosage is large are solved. Based on the principle of achieving the same goal by different ways, the three drugs acting on different mechanisms are combined, the drugs are synergistic and interact, the effect of the drugs is superior to the summing effect of the independent drug solid, and therefore the purpose of treating or preventing cardiovascular and cerebrovascular diseases is achieved. Paeoniflorin, hydroxyl safflower pigment A and rutin are different in action mechanisms in the aspect of treating the cardiovascular and cerebrovascular diseases and have the synergistic effect when matched in the application process, and the treatment effect is superior to that of single application only when the three drugs are combined together to be applied.
Description
technical field [0001] The invention relates to a pharmaceutical composition for treating cerebral infarction or / and coronary heart disease angina pectoris. Background technique [0002] my country is a country with a high incidence of cerebrovascular diseases. With the continuous improvement of people's material living standards and the increase of the aging population, the incidence is rapidly increasing. Cerebral infarction, cerebral arteriosclerosis, coronary heart disease, angina pectoris and other cardiovascular and cerebrovascular diseases seriously threaten human life and health. According to epidemiological investigations, the incidence and death of cardiovascular and cerebrovascular diseases have The mortality rate of cardiovascular and cerebrovascular diseases in my country has jumped to the top of various diseases. [0003] Cerebral infarction refers to multiple ischemic softening infarcts in the brain, also known as multiple encephalomalacia, accompanied by para...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more